No trial has tested phentermine with Ozempic. The phentermine label says combining it with any other weight-loss drug is not recommended [1]. The reason given is that safety and efficacy have not been established. The closest trial added phentermine to liraglutide, an older daily GLP-1 [2]. Over 12 weeks, 45 adults lost 1.6 percent more on phentermine against 0.1 percent on placebo. That difference was not significant.
This page covers the pairing only. The full list of alternatives is in what weight loss drugs there are besides Ozempic. Stalled weight loss, the usual reason for asking, is covered in why weight loss plateaus on a GLP-1.
What the phentermine label says
The label sets four rules [1]:
- Phentermine is a short-term treatment, for a few weeks.
- It is indicated as monotherapy.
- Safety and efficacy with any other weight-loss drug are not established. That covers prescription drugs, over-the-counter products and herbal products.
- Coadministration with those products is not recommended.
Phentermine is a Schedule IV controlled substance. Its listed reactions include raised blood pressure, a fast heart rate and palpitations. The label advises caution in patients with even mild hypertension.
The label does not name semaglutide or tirzepatide. The rule covers them because it covers every prescription weight-loss drug.
The one trial: phentermine added to liraglutide
The trial enrolled 45 adults who had already lost 12.6 percent of their weight [2]. That loss came from a year of liraglutide 3.0 mg and intensive behavioral treatment. They were then randomized, double-blind, to add phentermine 15 mg or placebo for 12 weeks.
Results at week 12:
- Further weight loss: 1.6 percent on phentermine, 0.1 percent on placebo (p = 0.073).
- A further 5 percent or more: 2 people (9.1%) against 1 (4.3%).
- Kept the full earlier loss: 86.4 percent against 69.9 percent (p = 0.125).
Hunger and food preoccupation fell more on phentermine in the first 8 weeks. The combination appeared well tolerated. The authors concluded it did not add clinically meaningful weight loss.
Three limits apply. The GLP-1 was liraglutide, not semaglutide. The sample was 45 people. The trial ran 12 weeks, and safety over a longer course was not measured.
How each drug performs alone
The single-drug trials started from full weight, so their results do not compare directly with the add-on trial. A 2024 review pooled them against placebo [3]. Semaglutide gave 11.4 percent more weight loss, across 5 trials and 4,421 people. Tirzepatide 15 mg gave 12.4 percent more. Phentermine-topiramate, the combination capsule, gave 8.0 percent more.
A 2025 meta-analysis covered 56 trials and 60,307 patients [4]. Semaglutide and tirzepatide each exceeded 10 percent total weight loss against placebo. Only two of those trials tested phentermine-topiramate. How weight loss trades against dropout across these drugs is in the 262-trial ranking.
A 2026 review of combination regimens reached a general finding [5]. Adding an approved obesity drug to a GLP-1 was generally additive, not synergistic. It also brought more complexity, cost and adverse-event risk.
Heart rate and blood pressure
Semaglutide raises resting heart rate. On Wegovy, mean increases were 1 to 4 beats per minute against placebo [6]. A rise of 20 beats or more at any visit occurred in 26 percent against 16 percent. The label says to monitor heart rate.
Phentermine lists a fast heart rate and raised blood pressure among its reactions [1]. No study reported heart rate or blood pressure on the two drugs together. How GLP-1 drugs behave in people with high blood pressure is covered in the resistant hypertension evidence.